ArticleScientific reports2025
The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
To evaluate the clinical value of polyethylene glycolized recombinant human granulocyte-stimulating factor (PEG-rhG-CSF) for hematopoietic reconstitution after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) patients. This study analyzed data from 70 NDMM patients undergoing ASCT, with 33 receiving PEG-rhG-CSF and 37 receiving rhG-CSF. The median time of neutrophil and platelet engraftment, median transfusions of blood products, treatment-related adverse reactions, long-term hematopoietic reconstitution and economic benefits were compared between the two groups. Both groups had similar median neutrophil engraftment, but PEG-rhG-CSF resulted in slower platelet engraftment (13.7 vs. 11.4 days, p < 0.001), more platelet transfusions (2.9 vs. 1.6 units, p < 0.001), higher incidence of grade ≥ 3 diarrhea (60.6 vs. 29.7%, p = 0.006), longer diarrhea duration (9.0 vs. 5.5 days, p = 0.004), and higher costs (RMB 77,126 vs. RMB 68,361, p = 0.027). PEG-rhG-CSF support post-ASCT in NDMM led to slower platelet engraftment, greater platelet transfusion requirements, increased incidence and duration of severe diarrhea, and greater costs, indicating its potential as an expensive treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.